

February 27, 2017



# **Interpace Diagnostics to Present New Data on Thyroid Product Performance**

## **Four Posters Accepted on ThyGenX® and ThyraMIR® to be Presented at USCAP**

PARSIPPANY, N.J., Feb. 27, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, announced today the acceptance of four posters to be presented at the upcoming United States and Canadian Academy of Pathology (USCAP) meeting being held March 4-10, 2017 in San Antonio, Texas.

The posters reflect a review of data from the Company's extensive experience in molecular thyroid testing, including experience with over 5000 analyses of indeterminate thyroid nodules using its combined mutational (ThyGenX®) and microRNA classifier (ThyraMIR®) testing format. Fundamental insights into the mechanism of thyroid cancer development and progression are reported as well as a comprehensive statistical analysis of the mutational and microRNA profiling features representing the largest integrated analysis of DNA and RNA alterations in existence for commercially available molecular products in the area of thyroid cancer.

The United States and Canadian Academy of Pathology (USCAP) has been the most prestigious provider of continuing medical education (CME) for pathologists globally for more than a century, superbly integrating CME into the process for improving professional practice and patient outcomes by reducing the gap between evidence-based practices and adoption of those practices into clinical care. The organization boasts a membership of 10,000 Pathologists and other practitioners committed to this goal.

The accepted posters that will be presented at the conference are entitled "The Role of miRNA Expression Analysis in Needle Aspirate Cytology of Indeterminate Thyroid Nodules", "Clinical and Biological Significance of Common Mutational Genotypes of Thyroid Follicular Neoplasia", "Biological Aggressiveness of Thyroid Neoplasia Depends on the Strength of the Genetic Mutation and Associated Cellular Interaction", and "MicroRNA Profiling Complements Microscopic/Mutational Analysis by Defining Alternative Pathways of Carcinogenesis."

According to Jack Stover, President & CEO of Interpace, "We are pleased that this work has been accepted for presentation at the upcoming USCAP meeting. The acceptance of these four posters by this prestigious international organization reflects the strength of our ongoing commitment to demonstrate the exceptional clinical utility of our tests globally."

### **About Thyroid Nodules, ThyGenX and ThyraMIR testing**

According to the American Thyroid Association, approximately 15% to 30% of the 525,000

thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX® and ThyraMIR®.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers.

### **About Interpace Diagnostics Group, Inc.**

Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at [www.interpacediagnostics.com](http://www.interpacediagnostics.com)

Interpace Diagnostics is a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

### **Forward Looking Statements**

*This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-*

*looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's ability to adequately finance the business, its ability to restructure its debt and other obligations, the market's acceptance of its molecular diagnostic tests, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and our ability to maintain our NASDAQ listing. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's filings with the SEC, including without limitation, the Annual Report on Form 10-K filed with the SEC on March 30, 2016, as amended on April 29, 2016 and June 14, 2016, the Quarterly Report on Form 10-Q filed with the SEC on November 17, 2016, and the prospectus supplement and accompanying prospectus related to the offering that was filed with the SEC. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

#### CONTACTS:

Interpace Diagnostics  
Investor Relations:

Paul Kuntz  
RedChip  
[Paul@Redchip.com](mailto:Paul@Redchip.com)

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/interpace-diagnostics-to-present-new-data-on-thyroid-product-performance-300413835.html>

SOURCE Interpace Diagnostics Group, Inc.